91.52%, which is based on the Criteria of Total Value of Consideration, which is the highest result. Including of the Company does not have any assets acquired or disposed of during the 6 months prior to
www.interpharma.co.th 6. Approve to present to the Shareholders' Meeting to consider and approve the issuance of debentures in the amount not exceeding 300 million Baht. The total debt burden of the Company at any one
the same quarter of prior year by Baht 10.08 million or equivalent to 49.55%. For the 3 months period (quarter 2/2019), the Company has total revenues at Baht 1 35.78 million which increased compared to
decreased compared to the same quarter of prior year by Baht 17.26 million or equivalent to 62.79%. For the 3 months period (quarter 3 /2019), the Company has total revenues at Baht 146.68 million which
decreased compared to the same quarter of prior year by Baht 5.51 million, resulting gross profit at Baht 4.65 million but the Company has total comprehensive loss at Baht 7.85 million. Since the revenues of
had net pro 2019 was 449.87 million baht. A de prior year. The total revenue was 1,036.22 Interest expenses were 263.73 increase was due to additional of borrowing to support hire purchase loan
net profit of 2019 was 449.87 million baht. A de prior year. The total revenue was 1,036.22 Interest expenses were 263.73 increase was due to additional of borrowing to support hire purchase loan
by discount the price to competitive, accordingly the gross profit margin dropped the prior about 3%. Service and cost of service Revenue from service and cost of service sharply decreased when
translation is strictly for reference. Notification of the Office of the Securities and Exchange Commission No. Sor Jor. 63/2559 Re: Reporting of Information Disclosure of Debt Securities Issuers After Offer
(interest coverage ratio : ICR) (เท่า) (. หนี2 สินที;มีภาระดอกเบี2ยต่อกาํไรก่อนดอกเบี2ยจ่าย ภาษีเงินได ้ค่าเสื;อมราคาและ ค่าตดัจาํหน่าย (interest bearing debt to EBITDA ratio) (เท่า) I. ความสามารถในการชาํระภา